APG Asset Management US’s BioMarin Pharmaceuticals BMRN Stock Holding History

APG Asset Management US’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,934	Closed	-$216K	–	73
2025 Q3	$216K	Hold	3,934	–	–	﹤0.01%	184
2025 Q2	$221K	Hold	3,934	–	–	﹤0.01%	188
2025 Q1	$267K	Hold	3,934	–	–	﹤0.01%	191
2024 Q4	$259K	Sell	3,934 -474	-11%	-$31.7K	﹤0.01%	198
2024 Q3	$309K	Sell	4,408 -49,400	-92%	-$4.13M	﹤0.01%	151
2024 Q2	$4.42M	Buy	53,808 +1,328	+3%	+$111K	0.03%	148
2024 Q1	$4.57M	Buy	52,480 +16,579	+46%	+$1.48M	0.03%	154
2023 Q4	$3.46M	Buy	+35,901	New	+$3.18M	0.02%	153

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

APG Asset Management US's BMRN Position: Q4 2025 in Review

APG Asset Management US sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 3,934 shares — an estimated $216K sold.

APG Asset Management US first reported a position in BMRN in Q4 2023 and held it in 8 quarters. The position peaked at $4.57M in Q1 2024. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

APG Asset Management US reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
APG Asset Management US sold 3,934 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $216K.
APG Asset Management US first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 8 quarters.
APG Asset Management US's BioMarin Pharmaceuticals position peaked at $4.57M in Q1 2024.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on APG Asset Management US's 13F filing for Q4 2025, filed 12 Feb 2026.